Literature DB >> 17409229

Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.

Zdenek Berger1, Hanno Roder, Amanda Hanna, Aaron Carlson, Vijayaraghavan Rangachari, Mei Yue, Zbigniew Wszolek, Karen Ashe, Joshua Knight, Dennis Dickson, Cathy Andorfer, Terrone L Rosenberry, Jada Lewis, Mike Hutton, Christopher Janus.   

Abstract

Neurofibrillary tangles (NFTs) are a pathological hallmark of Alzheimer's disease and other tauopathies, but recent studies in a conditional mouse model of tauopathy (rTg4510) have suggested that NFT formation can be dissociated from memory loss and neurodegeneration. This suggests that NFTs are not the major neurotoxic tau species, at least during the early stages of pathogenesis. To identify other neurotoxic tau protein species, we performed biochemical analyses on brain tissues from the rTg4510 mouse model and then correlated the levels of these tau proteins with memory loss. We describe the identification and characterization of two forms of tau multimers (140 and 170 kDa), whose molecular weight suggests an oligomeric aggregate, that accumulate early in the pathogenic cascade in this mouse model. Similar tau multimers were detected in a second mouse model of tauopathy (JNPL3) and in tissue from patients with Alzheimer's disease and FTDP-17 (frontotemporal dementia and parkinsonism linked to chromosome 17). Moreover, levels of the tau multimers correlated consistently with memory loss at various ages in the rTg4510 mouse model. Our findings suggest that accumulation of early-stage aggregated tau species, before the formation of NFT, is associated with the development of functional deficits during the pathogenic progression of tauopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409229      PMCID: PMC6672413          DOI: 10.1523/JNEUROSCI.0587-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  209 in total

Review 1.  Are tangles as toxic as they look?

Authors:  Tara L Spires-Jones; Katherine J Kopeikina; Robert M Koffie; Alix de Calignon; Bradley T Hyman
Journal:  J Mol Neurosci       Date:  2011-06-03       Impact factor: 3.444

2.  Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.

Authors:  Melissa J Alldred; Karen E Duff; Stephen D Ginsberg
Journal:  Neurobiol Dis       Date:  2011-11-07       Impact factor: 5.996

3.  Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption.

Authors:  Emmalee M Jones; Manish Dubey; Phillip J Camp; Briana C Vernon; Jacek Biernat; Eckhard Mandelkow; Jaroslaw Majewski; Eva Y Chi
Journal:  Biochemistry       Date:  2012-03-14       Impact factor: 3.162

Review 4.  Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology.

Authors:  Daniel J Glass; Steven E Arnold
Journal:  Alzheimers Dement       Date:  2011-12-03       Impact factor: 21.566

5.  Accelerated neurodegeneration through chaperone-mediated oligomerization of tau.

Authors:  Laura J Blair; Bryce A Nordhues; Shannon E Hill; K Matthew Scaglione; John C O'Leary; Sarah N Fontaine; Leonid Breydo; Bo Zhang; Pengfei Li; Li Wang; Carl Cotman; Henry L Paulson; Martin Muschol; Vladimir N Uversky; Torsten Klengel; Elisabeth B Binder; Rakez Kayed; Todd E Golde; Nicole Berchtold; Chad A Dickey
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 6.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

Review 7.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

8.  Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.

Authors:  Chad Dickey; Clara Kraft; Umesh Jinwal; John Koren; Amelia Johnson; Laura Anderson; Lori Lebson; Daniel Lee; Dennis Dickson; Rohan de Silva; Lester I Binder; David Morgan; Jada Lewis
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

Review 9.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

10.  Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.

Authors:  Mathew A Sherman; Michael LaCroix; Fatou Amar; Megan E Larson; Colleen Forster; Adriano Aguzzi; David A Bennett; Martin Ramsden; Sylvain E Lesné
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.